Innovations in Hepatitis C Screening and Treatment

Overview

Journal Hepatol Commun

Specialty Gastroenterology

Date 2021 Mar 8

PMID 33681673

Citations 18

Authors

Arpan A Patel

Aileen Bui

Eian Prohl

Debika Bhattacharya

Su Wang

Andrea D Branch

Ponni V Perumalswami

Affiliations

Soon will be listed here.

Abstract

New therapies offer hope for a cure to millions of persons living with hepatitis C virus (HCV) infection. HCV elimination is a global goal that will be difficult to achieve using the traditional paradigms of diagnosis and care. The current standard has evolved toward universal HCV screening and treatment, to achieve elimination goals. There are several steps between HCV diagnosis and cure with major barriers along the way. Innovative models of care can address barriers to better serve hardly reached populations and scale national efforts in the United States and abroad. Herein, we highlight innovative models of HCV care that aid in our progress toward HCV elimination.

Citing Articles

Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years.

Torre P, Festa M, Sarcina T, Masarone M, Persico M Viruses. 2024; 16(11).

PMID: 39599906 PMC: 11598908. DOI: 10.3390/v16111792.

Optimizing Hepatitis C Treatment Monitoring: Is Sustained Virologic Response at 4 Weeks Becoming the New Standard?.

Milosevic I, Filipovic A, Beronja B, Mitrovic N, Ruzic M, Simic J Microorganisms. 2024; 12(10).

PMID: 39458359 PMC: 11509943. DOI: 10.3390/microorganisms12102050.

Post-Diagnosis HCV RNA Testing Rates Prior to HCV Treatment Among People Living With HIV With HCV Antibody Positivity in the Asia-Pacific Region.

Rupasinghe D, Choi J, Kumarasamy N, Pujari S, Khol V, Somia I J Viral Hepat. 2024; 31(11):686-699.

PMID: 39115260 PMC: 11496006. DOI: 10.1111/jvh.13993.

Outcomes and Barriers Associated with Telehealth-Based Hepatitis C Treatment During Early Phases of the COVID-19 Pandemic.

Chen P, Truong J, Kawamoto J, Bhattacharya D, Patel A Fed Pract. 2024; 41(3):88-92.

PMID: 38835674 PMC: 11147438. DOI: 10.12788/fp.0460.

The effect of first-wave COVID-19 restrictions on HCV testing in Alberta, Canada: A trend analysis from 2019 to 2022.

Thompson L, Plitt S, Zhuo R, Charlton C Can Liver J. 2024; 7(2):273-285.

PMID: 38746866 PMC: 11089476. DOI: 10.3138/canlivj-2023-0027.

References

Chaillon A, Rand E, Reau N, Martin N . Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis. 2019; 69(11):1888-1895. PMC: 7188080. DOI: 10.1093/cid/ciz063. View

Prinsenberg T, Rebers S, Boyd A, Zuure F, Prins M, Van Der Valk M . Dried blood spot self-sampling at home is a feasible technique for hepatitis C RNA detection. PLoS One. 2020; 15(4):e0231385. PMC: 7156069. DOI: 10.1371/journal.pone.0231385. View

Iversen J, Dore G, Catlett B, Cunningham P, Grebely J, Maher L . Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. J Hepatol. 2018; 70(1):33-39. DOI: 10.1016/j.jhep.2018.09.030. View

Fluegge K, Bresnahan M, Laraque F, Litwin A, Perumalswami P, Shukla S . Evaluating reimbursement of integrated support services using chronic care management (CCM) codes for treatment of hepatitis C among Medicare beneficiaries. J Healthc Risk Manag. 2019; 39(2):31-40. DOI: 10.1002/jhrm.21389. View

Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D . Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011; 364(23):2199-207. PMC: 3820419. DOI: 10.1056/NEJMoa1009370. View

Doyle J, Scott N, Sacks-Davis R, Pedrana A, Thompson A, Hellard M . Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia. Aliment Pharmacol Ther. 2019; 49(9):1223-1229. DOI: 10.1111/apt.15210. View

Martinello M, Hajarizadeh B, Dore G . Hepatitis C elimination in Australia: progress and challenges. Med J Aust. 2020; 212(8):362-363. DOI: 10.5694/mja2.50584. View

Norton B, Bachhuber M, Singh R, Agyemang L, Arnsten J, Cunningham C . Evaluation of contingency management as a strategy to improve HCV linkage to care and treatment in persons attending needle and syringe programs: A pilot study. Int J Drug Policy. 2019; 69:1-7. PMC: 6704472. DOI: 10.1016/j.drugpo.2019.02.009. View

Nelson P, Mathers B, Cowie B, Hagan H, Des Jarlais D, Horyniak D . Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011; 378(9791):571-83. PMC: 3285467. DOI: 10.1016/S0140-6736(11)61097-0. View

10.

Millbourn C, Lybeck C, Psaros Einberg A, Nordin M, Lindh G, Hokeberg I . Anti-HCV prevalence and risk factor-based screening for hepatitis C in pregnant women and their partners in Sweden. Infect Dis (Lond). 2020; 52(11):776-785. DOI: 10.1080/23744235.2020.1784456. View

11.

Cunningham W, Weiss R, Nakazono T, Malek M, Shoptaw S, Ettner S . Effectiveness of a Peer Navigation Intervention to Sustain Viral Suppression Among HIV-Positive Men and Transgender Women Released From Jail: The LINK LA Randomized Clinical Trial. JAMA Intern Med. 2018; 178(4):542-553. PMC: 5885257. DOI: 10.1001/jamainternmed.2018.0150. View

12.

Akiyama M, Columbus D, MacDonald R, Jordan A, Schwartz J, Litwin A . Linkage to hepatitis C care after incarceration in jail: a prospective, single arm clinical trial. BMC Infect Dis. 2019; 19(1):703. PMC: 6686449. DOI: 10.1186/s12879-019-4344-1. View

13.

Lau M, Beste L, Kryskalla J, Rongey C . Hepatitis C Clinical Dashboards: Improving Liver Specialty Care Access and Quality. Fed Pract. 2019; 32(Suppl 2):32S-36S. PMC: 6375504. View

14.

Harris R, Ramsay M, Hope V, Brant L, Hickman M, Foster G . Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health. 2011; 22(2):187-92. DOI: 10.1093/eurpub/ckr083. View

15.

U S Department Of Health And Human Services . Opioid abuse in the United States and Department of Health and Human Services actions to address opioid-drug-related overdoses and deaths. J Pain Palliat Care Pharmacother. 2015; 29(2):133-9. DOI: 10.3109/15360288.2015.1037530. View

16.

Saab S, Le L, Saggi S, Sundaram V, Tong M . Toward the elimination of hepatitis C in the United States. Hepatology. 2017; 67(6):2449-2459. DOI: 10.1002/hep.29685. View

17.

Graf C, Mucke M, Dultz G, Peiffer K, Kubesch A, Ingiliz P . Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis. Clin Infect Dis. 2019; 70(11):2355-2365. DOI: 10.1093/cid/ciz696. View

18.

de la Flor C, Porsa E, Nijhawan A . Opt-out HIV and Hepatitis C Testing at the Dallas County Jail: Uptake, Prevalence, and Demographic Characteristics of Testers. Public Health Rep. 2017; 132(6):617-621. PMC: 5692159. DOI: 10.1177/0033354917732755. View

19.

Jhaveri R, Broder T, Bhattacharya D, Peters M, Kim A, Jonas M . Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now. Clin Infect Dis. 2018; 67(10):1493-1497. PMC: 6927857. DOI: 10.1093/cid/ciy586. View

20.

Ho C, Preston C, Fredericks K, Doorley S, Kramer R, Kwan L . A unique model for treating chronic hepatitis C in patients with psychiatric disorders, substance abuse, and/or housing instability. J Addict Med. 2013; 7(5):320-4. DOI: 10.1097/ADM.0b013e31829b1a6c. View